However, intergroup comparisons did not show significant difference in ESR, CRP, and RF contents after treatment (P > 0.05), indicating that there was no significant difference in the improvement of RA serological disease markers between the two groups of RA patients (Table 2). This evidence concerns the gene ESR1 and rheumatoid arthritis.